Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a

Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a

Abstract Background Green tea drinking has been proven to lower lipid and exert cardiovascular protection, while the potential mechanism has not been fully determined. This study was to investigate whether the beneficial impact of epigallocatechingallate (EGCG), a type of catechin in green tea on li...

Full description

Bibliographic Details
Main Authors:	Chuan-Jue Cui, Jing-Lu Jin, Lin-Na Guo, Jing Sun, Na-Qiong Wu, Yuan-Lin Guo, Geng Liu, Qian Dong, Jian-Jun Li
Format:	Article
Language:	English
Published:	BMC 2020-05-01
Series:	Journal of Translational Medicine
Subjects:	Epigallocatechingallate Proprotein convertase subtilisin/kexin type 9 Low density lipoprotein receptor Low density lipoprotein cholesterol Hepatocyte nuclear factor-1α Forkhead box class O 3a
Online Access:	http://link.springer.com/article/10.1186/s12967-020-02362-4

Similar Items

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]
by: Brandon Ason, et al.
Published: (2014-11-01)

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]
by: Frederick J. Raal, et al.
Published: (2016-06-01)

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
by: Øystein L. Holla, et al.
Published: (2011-10-01)

Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
by: Yi Luo, et al.
Published: (2009-08-01)

PCSK9 Biology and Its Role in Atherothrombosis
by: Cristina Barale, et al.
Published: (2021-05-01)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
by: Dennis T. Ko, et al.
Published: (2018-11-01)

Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population
by: Ilaria Guella, et al.
Published: (2010-11-01)

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
by: Sarah J. Duellman, et al.
Published: (2017-08-01)

Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
by: R. Huijgen, et al.
Published: (2012-05-01)

The PCSK9 decade
by: Gilles Lambert, et al.
Published: (2012-12-01)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
by: Payal Kohli, et al.
Published: (2016-05-01)

Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice[S]
by: Vikram Ravindra Shende, et al.
Published: (2015-04-01)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
by: Michael D. Shapiro, et al.
Published: (2019-02-01)

Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE<sup>−/−</sup> Mice
by: Lili Gu, et al.
Published: (2019-11-01)

Effects of Serum Estradiol on Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Lipid Profiles in Women Undergoing In Vitro Fertilization
by: Anna Papanikolaou, et al.
Published: (2024-01-01)

Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody[S]
by: Krista M. Schroeder, et al.
Published: (2015-11-01)

Familial Hypercholesterolemia
by: FENG Siqin, et al.
Published: (2023-01-01)

In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction
by: Bowen Lou, et al.
Published: (2022-10-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
by: Huang CC, et al.
Published: (2019-10-01)

Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture
by: Majambu Mbikay, et al.
Published: (2014-01-01)

PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults
by: Matthew T. Mefford, et al.
Published: (2019-11-01)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
by: Niki Katsiki, et al.
Published: (2023-04-01)

Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies
by: Arrigo F.G. Cicero, et al.
Published: (2022-01-01)

THE INVOLVEMENT PROPROTEIN CONVERTASE SUBTILISIN/KEXIN OF TYPE 9 IN THE PATHOGENESIS OF ATHEROSCLEROSIS (LITERATURE REVIEW)
by: A. M. Chaulin
Published: (2020-03-01)

Computational Study of PCSK9-EGFA Complex with Effective Polarizable Bond Force Field
by: Jian Chen, et al.
Published: (2018-01-01)

Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy
by: Jonathan Grimm, et al.
Published: (2021-04-01)

Novel Low-Density Lipoprotein Cholesterol Reduction Therapies for the Secondary Prevention of Cardiovascular Disease
by: Xing Wang, et al.
Published: (2023-10-01)

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
by: Erik Stroes, et al.
Published: (2016-09-01)

Lipid Testing Trends Before and After Hospitalization for Myocardial Infarction Among Adults in the United States, 2008–2019
by: Levintow SN, et al.
Published: (2022-06-01)

A reassessment of the Japanese clinical diagnostic criteria of familial hypercholesterolemia in a hospital-based cohort using comprehensive genetic analysis
by: Hayato Tada, et al.
Published: (2020-11-01)

High-Throughput Screening Identifies MicroRNAs Regulating Human PCSK9 and Hepatic Low-Density Lipoprotein Receptor Expression
by: Coen van Solingen, et al.
Published: (2021-07-01)

Treatment of Hyperlipidemia: Consensus and Controversies
by: Christoph H Saely, et al.
Published: (2017-01-01)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
by: Aureli Luquero, et al.
Published: (2021-03-01)

PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
by: Mali Liu, et al.
Published: (2010-09-01)

Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i
by: Erin S. Mackinnon, et al.
Published: (2023-01-01)

Application of evolocumab in patients with coronary heart disease complicated with mild renal insufficiency
by: Zhang Yu, Wu Bin, Feng Jiaxu, Wang Rutao, Yuan Ming
Published: (2023-10-01)

Association of Lowering Low‐Density Lipoprotein Cholesterol With Contemporary Lipid‐Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta‐Analysis
by: Safi U. Khan, et al.
Published: (2019-04-01)

Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts
by: Shamanna S Iyengar
Published: (2016-01-01)

Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study
by: Massimiliano Ruscica, et al.
Published: (2017-05-01)